Vinehealth Seed
🏦 Potential exit path:
M&A
Founded in 2018, Vinehealth has built an app applying behavioral science and AI to deliver highly personalized support for cancer patients at scale. The platform also acts as a channel through which patients can be remotely monitored by their clinicians as they provide feedback on symptoms and report any treatment side effects. On the other hand, the technology makes it easier to gather patient-reported outcome (PRO) data to inform health service delivery, drug development and research. The company has been financially supported by the UK's National Health Service (NHS).Select partners: The Royal Marsden NHS Foundation Trust, The National Hospital of Neurology and Neurosurgery, Health Foundation.
Founded 2018
Employees 20+
Diseases & Conditions Cancer
Sections Patient Engagement
Funding 💰
Total
$8.5M
Last round
🔗
$5.5M
December 3, 2021.
December 3, 2021.
Select investors Talis Capital, Playfair Capital, Ascension Health System, KHP MedTech Innovations, VOYAGERS Health-Tech Fund
Key people 🧑🤝🧑
- Rayna Patel - Co-founder & CEO
- Georgina Kirby - Co-Founder & CTO
- Will Jones - Tech Lead
- Jack Ziomek - Senior Product Owner
- Andy Freeburn - Head of Product and Design
Highlights ⭐
- Solving a real problem: Vinehealth wants to solve a real problem and make it easier for cancer patients to better manage their disease from home through a complex healthcare system.
- The industry believes in Vinehealth: In addition to traditional VCs, the company also got backing from other healthcare players, which obviously think Vinehealth is onto something. These include Faisal Mehmud, VP and former medical director of Bristol Myers Squibb; and KHP MedTech Innovations, a collaboration between King's College London, King's College Hospital NHS Foundation Trust and Guy's and St Thomas' NHS Trust.
- Eye on the US market: Vinehealth is gearing up to expand in the U.S. market. That was one of the main ideas behind its Seed financing round. 🔗
- TechCrunch's startup to watch: The tech publication caught Vinehealth in March 2019 during Entrepreneur First's 11th Demo Day in London. At that time, it noted that co-founders are "rather well qualified" and that the company has a "great advisory board." 🔗
Video ▶️
Awards & Recognitions 🏆
Quotes 💬
“
We'd been keeping a close eye on Vinehealth's growth for several months before we invested in the company, given its unique value proposition where healthcare outcomes work in direct correlation with financial outcomes. It's a win-win-win for patients, hospitals and pharmaceutical companies, which is rarely the case in the healthcare space where parties are often at odds with one another.
— Beatrice Aliprandi, principal at Talis Capital
Last update:
August 16, 2022
Disclaimer: The content on this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances.